Drug intelligence / Profile preview

dexmedetomidine + magnesium sulphate

Development stage
Approved
Modality
Small Molecules
Administration
Intravenous, Perineural
01

Overview

Dexmedetomidine + magnesium sulphate is a combination of two agents used primarily as adjuncts in anesthesia and critical care settings. Dexmedetomidine is a highly selective alpha-2 adrenergic receptor agonist that provides sedation, anxiolysis, and analgesia without significant respiratory depression. Magnesium sulphate acts as an NMDA receptor antagonist, calcium channel blocker, and central nervous system depressant with anticonvulsant properties. The combination has been studied for its synergistic effects in several clinical scenarios: - In alcohol withdrawal delirium (delirium tremens), the combination shortens the duration of delirium more effectively than either agent alone or standard therapy, improves hemodynamic stability (mean arterial pressure and heart rate), normalizes plasma cortisol and serotonin levels (biomarkers of stress response), does not adversely affect kidney or liver function, and reduces complications such as hypotension or bradycardia compared to monotherapy[1][5][2]. - As adjuvants to local anesthetics (e.g., levobupivacaine) for regional blocks such as spermatic cord block during testicular surgery, the combination prolongs postoperative analgesia duration more than either agent alone[3]. - Both drugs are also individually used for controlled hypotension during surgery to improve surgical field quality[9]. The mechanism involves combined alpha-2 adrenergic agonism by dexmedetomidine (reducing sympathetic outflow) with NMDA antagonism/calcium channel blockade by magnesium sulphate (dampening neuronal excitability). This results in enhanced sedation/analgesia with improved safety profile.

Brand names
Precedex
Other names
dexmedetomidine and magnesium sulfatedexmedetomidine and magnesium sulphate
02

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)ADRA2A (α2A)CaV (Voltage-gated calcium channel protein complex)

Beyond the preview

Go deeper on dexmedetomidine + magnesium sulphate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dexmedetomidine + magnesium sulphate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call